Medical Crossfire: A Payer and Neurologist Discussion on the Shifting Paradigm of Alzheimer

https://www.pharmacytimes.org/on-demand/an-american-journal-of-managed-care-medical-crossfire-a-payer-and-neurologist-discussion-on-the-shifting-paradigm-of-alzheimers-disease-treatment

Related Videos

Related Content

Advertisement

June 12th 2025

RGX-202 Gene Therapy Improves DMD Trajectory, Biomarkers

Rose McNulty

Participants with Duchenne muscular dystrophy (DMD) who received RGX-202 demonstrated functional improvement and better outcomes than natural history controls for all measures.

June 10th 2025

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

Brooke McCormick Julia D. Lucaci, PharmD, MS

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

June 12th 2025

Zilucoplan Shows Rapid, Durable, Steroid-Sparing Benefits in gMG

Maggie L. Shaw

Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).

June 3rd 2025

Managed Care Cast News Roundup: June 3, 2025

Giuliana Grossi

A quick roundup episode of major health policy developments, from shifting COVID-19 vaccine guidance and scientific publishing controversies to rising cancer care costs and the impact of oncology biosimilars.

June 12th 2025

Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

Laura Joszt, MA

Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, demonstrating efficacy with no new safety signals.

June 12th 2025

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

Giuliana Grossi

The FDA approved mitomycin intravesical solution (Zusduri) for patients with recurrent low-grade intermediate risk non–muscle-invasive bladder cancer (NMIBC).

Related Content

Advertisement

June 12th 2025

RGX-202 Gene Therapy Improves DMD Trajectory, Biomarkers

Rose McNulty

Participants with Duchenne muscular dystrophy (DMD) who received RGX-202 demonstrated functional improvement and better outcomes than natural history controls for all measures.

June 10th 2025

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

Brooke McCormick Julia D. Lucaci, PharmD, MS

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

June 12th 2025

Zilucoplan Shows Rapid, Durable, Steroid-Sparing Benefits in gMG

Maggie L. Shaw

Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).

June 3rd 2025

Managed Care Cast News Roundup: June 3, 2025

Giuliana Grossi

A quick roundup episode of major health policy developments, from shifting COVID-19 vaccine guidance and scientific publishing controversies to rising cancer care costs and the impact of oncology biosimilars.

June 12th 2025

Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

Laura Joszt, MA

Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, demonstrating efficacy with no new safety signals.

June 12th 2025

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

Giuliana Grossi

The FDA approved mitomycin intravesical solution (Zusduri) for patients with recurrent low-grade intermediate risk non–muscle-invasive bladder cancer (NMIBC).